Medpace Holdings, Inc. (MEDP)
| Market Cap | 5.78B |
| Revenue (ttm) | 925.93M |
| Net Income (ttm) | 145.38M |
| Shares Out | 35.64M |
| EPS (ttm) | 3.84 |
| PE Ratio | 41.41 |
| Forward PE | 36.90 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $159.02 |
| Previous Close | $161.11 |
| Change ($) | -2.09 |
| Change (%) | -1.30% |
| Day's Open | 161.60 |
| Day's Range | 158.51 - 162.49 |
| Day's Volume | 213,890 |
| 52-Week Range | 58.72 - 177.12 |
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What do they know, and how? By a community of over 100,000 worldwide employee information gatherers reporting back to Market-Maker HQ trading desks. Based on traders' hedges of short positions...
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2020 financial results after the market cl...
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference: Credit Suisse Healthcare Conference Da...
Medpace Holdings' (MEDP) CEO August Troendle on Q3 2020 Results - Earnings Call Transcript
Medpace (MEDP) delivered earnings and revenue surprises of 4.63% and 2.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Medpace Hldgs (NASDAQ:MEDP) moved lower by 1% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 53.52% year over year to $...
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Financial Re...
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2020 financial results after the market close on Monday, Oc...
Top Ranked Momentum Stocks to Buy for August 28th
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference in September: Baird's Global Healthcare...
Top Ranked Momentum Stocks to Buy for August 26th
Top Ranked Momentum Stocks to Buy for August 24th
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for August 20th
The service sector index read 58.1% in July, a 17-month high. Lest we forget, a reading above 48.5% indicates expansion of the broader economy.
Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q2 2020 Results - Earnings Call Transcript
The clinical trial company's second-quarter financial results were better than expected.
Medpace Holdings stock soared Tuesday to a record high after the provider of clinical testing and research services for drugmakers late Monday forecast better-than-expected revenue for 2020. T...
Medpace (MEDP) delivered earnings and revenue surprises of 61.90% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) delivered earnings and revenue surprises of 52.38% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace stock jumped in after-hours trading Monday, after rising in the regular session, as second-quarter revenue and full-year revenue guidance handily beat Wall Street expectations.
Shares of Medpace Hldgs (NASDAQ:MEDP) moved higher by 15.7% in after-market trading after the company reported Q2 results.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2020.
Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The last time value stocks were in style, Abraham Lincoln still had a Pennsylvania Avenue address.
Medpace Holdings' (MEDP) CEO August Troendle on Q1 2020 Results - Earnings Call Transcript
Medpace (MEDP) delivered earnings and revenue surprises of -1.30% and 1.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q4 2019 Results - Earnings Call Transcript
Medpace (MEDP) delivered earnings and revenue surprises of 13.33% and 3.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Stock Is Up Over 100% In 14 Months, Yet The Sentiment Is Still Bearish On Medpace Holdings
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Helping people stricken with illness can be richly rewarding in more ways than one.
Many investors aren’t aware of the vital roles contract research organizations fulfill for pharmaceutical and biotech companies -- or of the billions they make each year for their services.
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q3 2019 Results - Earnings Call Transcript
Medpace (MEDP) delivered earnings and revenue surprises of 0.00% and -0.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Investment in mid-cap stocks is often recognized as a good portfolio diversification strategy during market fluctuations.
Nonfarm payroll reports show jobs addition in the private sector, these are five stocks to add to your portfolio.
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
As signs of deterioration emerge, the central bank may feel compelled to cut rate for the second time in September.
As of late, it has definitely been a great time to be an investor in Medpace Holdings, Inc. (MEDP).
New Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q2 2019 Results - Earnings Call Transcript
Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Near-Term Outlook for Medical Services Industry Looks Bright
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q1 2019 Results - Earnings Call Transcript
About MEDP
Medpace Holdings provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigil... [Read more...]
| Industry Diagnostics & Research | IPO Date Aug 11, 2016 |
| CEO August Troendle | Employees 3,600 |
| Stock Exchange NASDAQ | Ticker Symbol MEDP |
Financial Performance
In 2020, MEDP's revenue was $925.93 million, an increase of 7.54% compared to the previous year's $860.97 million. Earnings were $145.38 million, an increase of 44.74%.
Analyst Forecasts
According to 6 analysts, the average rating for MEDP stock is "Buy." The 12-month stock price forecast is 164.50, which is an increase of 3.45% from the latest price.